Literature DB >> 8766553

Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7.

R J Ray1, C J Paige, C Furlonger, S D Lyman, R Rottapel.   

Abstract

B cell development is influenced by interactions between B cell progenitors and stromal cells. The precise mechanisms by which these interactions regulate B cell differentiation are currently unknown. Flt3 ligand (FL) is a growth factor which stimulates the proliferation of stem cells and early progenitors. Mice deficient for the FLT3 receptor exhibit severe reductions in early B lymphoid progenitors. We have previously described a clonal assay in vitro which allows us to follow the entire B cell differentiation pathway from uncommitted progenitors to mature, immunoglobulin-secreting plasma cells. The growth factor combination of interleukin (IL)-11, mast cell growth factor (MGF) and IL-7 was shown to maintain the differentiation of these hematopoietic precursors into B cell progenitors capable of giving rise to functionally mature B cells in secondary cultures. Here, we show that FL in combination with IL-11 and IL-7 is sufficient to support the differentiation of uncommitted progenitors from day 10 yolk sac (AA4.1+) or day 12 fetal liver (AA4.1+ B220- Mac-1- Sca-1+) into the B lineage. The frequency of B cell progenitors obtained in these conditions was similar, if not better, than the frequency of B cell precursors that arose when cultured in IL-11+MGF+IL-7. Furthermore, the growth factor combination of IL-11+FL+ IL-7 was able to maintain the potential of bipotent precursors giving rise to both the B and myeloid lineages in secondary cultures. We also show that FL synergizes with IL-7 in the proliferation of committed B220+ pro-B cells and may contribute to the maintenance of an earlier pro-B cell population. Together, these results show that FL is important in supporting the differentiation and proliferation of early B cell progenitors in vitro.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8766553     DOI: 10.1002/eji.1830260715

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

1.  Repression of Flt3 by Pax5 is crucial for B-cell lineage commitment.

Authors:  Melissa L Holmes; Sebastian Carotta; Lynn M Corcoran; Stephen L Nutt
Journal:  Genes Dev       Date:  2006-04-15       Impact factor: 11.361

2.  Effects of autologous stromal cells and cytokines on differentiation of equine bone marrow-derived progenitor cells.

Authors:  Ute E Schwab; Rebecca L Tallmadge; Mary Beth Matychak; M Julia B Felippe
Journal:  Am J Vet Res       Date:  2017-10       Impact factor: 1.156

3.  Knockdown of Pu.1 by small interfering RNA in CD34+ embryoid body cells derived from mouse ES cells turns cell fate determination to pro-B cells.

Authors:  Gang-Ming Zou; Jian-Jun Chen; Mervin C Yoder; Wei Wu; Janet D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

4.  Murine germinal center B cells require functional Fms-like tyrosine kinase 3 signaling for IgG1 class-switch recombination.

Authors:  Mattias N D Svensson; Karin M E Andersson; Caroline Wasén; Malin C Erlandsson; Merja Nurkkala-Karlsson; Ing-Marie Jonsson; Mikael Brisslert; Mats Bemark; Maria I Bokarewa
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

Review 5.  Bench to bedside targeting of FLT3 in acute leukemia.

Authors:  Keith W Pratz; Mark J Levis
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

6.  FLT3/ITD AML and the law of unintended consequences.

Authors:  Mark Levis
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

7.  B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.

Authors:  Marianela Candolfi; James F Curtin; Kader Yagiz; Hikmat Assi; Mia K Wibowo; Gabrielle E Alzadeh; David Foulad; A K M G Muhammad; Sofia Salehi; Naomi Keech; Mariana Puntel; Chunyan Liu; Nicholas R Sanderson; Kurt M Kroeger; Robert Dunn; Gislaine Martins; Pedro R Lowenstein; Maria G Castro
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

Review 8.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

9.  An Atypical Splenic B Cell Progenitor Population Supports Antibody Production during Plasmodium Infection in Mice.

Authors:  Debopam Ghosh; Daniel J Wikenheiser; Brian Kennedy; Kathryn E McGovern; Johnasha D Stuart; Emma H Wilson; Jason S Stumhofer
Journal:  J Immunol       Date:  2016-07-22       Impact factor: 5.422

Review 10.  Structural and functional alterations of FLT3 in acute myeloid leukemia.

Authors:  Soheil Meshinchi; Frederick R Appelbaum
Journal:  Clin Cancer Res       Date:  2009-06-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.